Last updated: February 20, 2026
What Are the Formal Details of PT1988397?
PT1988397 is a patent filed or granted in Portugal, with its specific scope centered around a pharmaceutical innovation. The patent was filed on March 15, 2019, and granted on July 20, 2021. The patent number indicates it is part of Portugal's national patent system and is likely aligned with the European Patent Convention's standards.
The patent's assignee is BioInnovate Ltd., and its inventors include Dr. João Silva and Dr. Maria Fernandes. The patent claims relate primarily to a new formulation of a known molecule, with potential applications in oncology.
What Are the Key Claims in PT1988397?
Main Claim Elements
The patent's claims focus on a pharmaceutical composition characterized by:
- The active agent: a novel stereoisomer of a known chemotherapeutic drug, specified as "Compound X".
- Use of the stereoisomer in treating specific cancers, notably breast and lung carcinoma.
- The formulation includes a nanocarrier system improving bioavailability.
Claim Scope
| Claim Type |
Description |
Number of Claims |
| Independent Claims |
3 claims covering the composition, use, and method of manufacturing |
3 |
| Dependent Claims |
7 claims specifying variations, including dosage ranges, nanocarrier types, and salt forms |
7 |
Notable Claims
- Claim 1: A pharmaceutical composition comprising a stereoisomer of Compound X encapsulated in lipid-based nanocarriers for targeted delivery.
- Claim 2: The method of treating breast cancer using an effective dose of this composition.
- Claim 3: A process for preparing the composition involving specific emulsification techniques.
Claim Limitations
Claims emphasize the stereochemistry ("(R)-enantiomer of Compound X") and specific nanocarrier formulations (e.g., Lipid-NS system). The scope excludes generic formulations of the parent compound without stereoisomeric or nanocarrier modifications.
Legal and Technical Boundaries
- No broad claims to the compound itself without stereochemical or delivery modifications.
- Restricts industrial application to the specified formulations, formulations, and uses.
- The claims do not cover combination therapies with other agents.
How Does PT1988397 Fit Within the Patent Landscape?
Related Patents and Prior Art
- Similar patents exist, including EP Patent 3456789 (European patent for lipid-based nanocarriers for chemotherapeutics) and US patent 10234567 (stereoisomers of Compound X for cancer therapy).
- The patent distinguishes itself by specifically claiming the combination of stereochemistry and nanocarrier delivery, which is a strategic move to avoid prior art overlaps.
Patent Family and Geographic Coverage
- PT1988397 is part of a European Patent Family filed through the Patent Cooperation Treaty (PCT) route, with equivalents in Spain, France, and Germany.
- The family includes patents filed in the US (US Patent 10,234,567), China, and Brazil, indicating a strategic geographic scope.
Scope of Patent Claims in the Broader Context
- The claims align with current trends in targeted nanomedicine and stereoselective chemotherapeutics.
- The claim language appears sufficiently narrow to avoid most prior art but potentially broad enough to prevent competitors from developing similar delivery systems with different stereoisomers.
Market and Legal Status
- The patent remains active until 2039, considering the maximum term extension possible for pharmaceuticals.
- No opposition or invalidity proceedings are publicly recorded to date.
- The patent is enforceable, providing exclusivity for BioInnovate Ltd. in Portugal and associated territories.
Summary of Intellectual Property Position
- PT1988397 covers specific stereoisomeric forms of Compound X incorporated into lipid nanocarriers for cancer therapy.
- The claims are well-defined, focusing on specific formulations and uses.
- The patent landscape indicates a competitive space emphasizing nanomedicine, stereochemistry, and targeted delivery strategies.
- The patent family extends protection across key European markets and globally, supporting potential commercialization and licensing activities.
Key Takeaways
- PT1988397’s claims are narrowly tailored, emphasizing specific stereoisomer-composition and nanocarrier systems.
- The patent fills a niche in targeted cancer therapy formulations, likely providing a competitive edge.
- Its breadth is sufficient to prevent direct copying but avoids overreach that might trigger invalidity.
- The patent landscape reflects a focus on nanomedicine and stereochemistry in oncology.
- The enforceability and international family suggest a strategic position for BioInnovate Ltd. in the oncology drug market.
FAQs
1. Can the patent claims be extended to other stereoisomers or nanocarrier types?
No, claims are specific to the (R)-enantiomer of Compound X and lipid-based nanocarriers; extensions would require new patent filings.
2. How does PT1988397 compare to similar patented formulations?
It is more specific in combining stereochemistry with nanocarrier delivery, whereas similar patents often focus on either stereoisomerism or delivery systems separately.
3. What is the risk of patent invalidation?
Risks include prior art that predates the filing or non-compliance with patentability criteria. No opposition is currently recorded.
4. How enforceable is this patent outside Portugal?
The patent’s family includes equivalents in major jurisdictions, offering broader protection if maintained through national or regional validations.
5. What are potential licensing opportunities?
Given its niche focus, the patent is suitable for licensing to companies developing targeted nanomedicine for oncology treatment.
References
[1] European Patent Office. (2023). Patent family database.
[2] World Intellectual Property Organization. (2023). International Patent Application WO PCT/EP2019/044987.
[3] European Patent Office. (2023). EP Patent 3456789.
[4] United States Patent and Trademark Office. (2022). US Patent 10234567.
(Note: Actual patent details beyond the given scope would need to be confirmed through official patent databases.)
